Navigation Links
Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
Date:5/30/2008

- Primary study objectives include evaluation of safety and tolerability,

as well as selection of a recommended dose for Phase 2 trials -

ROCKVILLE, Md., May 30 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced solid tumors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"We are pleased to initiate this first human study of HGS1029, and we look forward to studying our IAP inhibitors both alone and in combination with other anti-cancer agents, including our TRAIL receptor antibodies," said Gilles Gallant, B. Pharm., Ph.D., Vice President, Clinical Research - Oncology, HGS.

HGS acquired exclusive worldwide rights (excluding Japan) to develop and commercialize HGS1029 (formerly AEG40826) and other IAP inhibitors from Aegera Therapeutics, Inc. in December 2007. When IAP proteins are over-expressed in cancer cells, they may help cancer cells resist apoptosis, or programmed cell death, and resume growth. The IAP inhibitors developed by Aegera, including HGS1029, are members of a new class of designed small-molecule drugs that block the biological activity of IAP proteins, thus allowing apoptosis to proceed and causing the cancer cells to die. Preclinical studies have shown that HGS1029 has significant anti-tumor activity alone and in combination with other anti-cancer agents, including the HGS TRAIL receptor antibodies, against a number of cancer types.

About the Phase 1 Trial Design

The primary obj
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... DUBLIN , October 24, 2014 ... has announced the addition of the "Global ... report to their offering.      (Logo: ... Concentrates Industry Report 2014 is a professional and ... hemodialysis concentrates industry with a focus on the ...
(Date:10/25/2014)... HOUSTON , Oct. 24, 2014   Metanome, ... of comprehensive metagenomic services and data analysis, was the ... Mass ) Phase I/II clinical trial of SER ... with recurrent Clostridium difficile infections (CDI). ... of Seres Health,s R&D and clinical programs. Such genomic ...
(Date:10/25/2014)... 2014 Burzynski Research Institute, Inc. (BRI) announced ... has given the company permission to conduct an open-label ... 3 months of age with a diffuse intrinsic brainstem ... of five treatment groups based on their age and ... DIPG. The primary study endpoint is a decrease in ...
Breaking Medicine Technology:Global and Chinese Hemodialysis Concentrates Industry Report 2014 2Global and Chinese Hemodialysis Concentrates Industry Report 2014 3Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2
... , MORRISTOWN, N.J. , May 7 Watson Pharmaceuticals, ... Laboratories, Inc. has reached a settlement with Teva Women ,s Health, ... estradiol tablets USP, 0.15 mg/0.03 mg) product. , ... On December 13, 2007 , Teva filed a ...
... , May 7 Patients treated ... clinical improvement at two years, according to interim ... today as a late-breaking clinical trial at the ... Annual Scientific Sessions. The prospective, single-arm study is ...
Cached Medicine Technology:Watson Reaches Settlement with Teva Over Seasonale(R) 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 3
(Date:10/25/2014)... October 25, 2014 The ... which verifies IT-accessibility for disabled users by disabled ... logo to Mackin Educational Resources of Burnsville, ... management system and to the Minnesota Alliance for ... "Own Best Medicine" website. Both organizations ...
(Date:10/25/2014)... October 25, 2014 Homeowners that are ... ‘gone bad’ need wonder no more. Clean Crawls ... should watch out for when it comes to insulation ... to the article released by Clean Crawls, can cause ... that any insulation that has deteriorated, become damp, or ...
(Date:10/25/2014)... Limbkeepers® announced today that they will be featured ... Jr, airing 1st QTR 2015 via Discovery Channel. Dates ... will focus on Limbkeepers® non compression knit sleeves, a ... arms, hands, and legs from abrasion, skin tears and ... help reduce injuries, allow for continued daily activities, and ...
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- Not getting the right ... colitis, a new study suggests. Those who sleep ... hours per night may be more prone to developing ... researchers report. The study authors concluded that duration and ... among patients with inflammatory bowel diseases. "Both short ...
(Date:10/25/2014)... Oct. 23, 2014 (HealthDay News) -- Current osteoporosis ... younger postmenopausal women at risk for osteoporosis-related fractures, ... to prevent fractures, we need tools that help ... injuries so that we can target these at-risk ... Crandall, professor of medicine in the division of ...
Breaking Medicine News(10 mins):Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... thing in medical research from the field of orthopedics is the use of ... to be true but read on to know more. , ... broken, and you have a cast and you are asked to wait for ... Imagine the amount of trauma and agony you would go through!// ...
... Ohio, the United States of America, have transplanted a bovine jugular ... due to a weakened valve of a vein in his right ... in man to treat varicose ulcers. , ... at Toledo, Ohio, are ecstatic that the procedure has succeeded very ...
... be round the corner as scientists have traced the pathway of ... with they have experimented on the rat brain and they are ... that such advances have been made vis-à-vis eating disorders. ... brain cells respond to hormones, among them two proteins called leptin ...
... scientists have created mice with unusually long memories raising hopes ... of helping people forget their distressing past. “This study has ... govern memory and learning in the brain,” said Isabelle Mansuy, ... , This breakthrough provides ...
... A herpes virus that causes infectious mononucleosis, Epstein-Barr virus (EBV), ... Hodgkin's disease. But no one has carefully studied the possible ... by Dr. Christina A. Clarke from Northern California Cancer Center ... This virus is believed to increase the risk for ...
... and wound healing has always been difficult terrain for scientists ... and understanding inter cellular mechanisms is the key to knowing ... Researchers led by Vito Quaranta at The ... protein that helps trigger the healing process -- also tells ...
Cached Medicine News:Health News:Scientists use plastic to help body make new bone!!!! 2
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
... Metal material and modularity into ... a fusion of technology and versatility ... for initial and long-term stability, but ... shell and liner options to address ...
The cementless biomEx cup can be used with both cemented and cementless femoral stems....
The Trilogy system builds on the success of the Harris/Galante Porous and HGP II cups by combining proven features with new technology designed to inhibit the formation and migration of polyethylene ...
Medicine Products: